- Home
- ALIS vs TIL Comparison
ALIS vs TIL Comparison
Compare ALIS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALIS | TIL |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 74.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALIS | TIL |
|---|---|---|
| Price | $9.94 | $7.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $100.67 |
| AVG Volume (30 Days) | 47.1K | ★ 182.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $5.67 |
| 52 Week High | $9.95 | $42.79 |
Technical Indicators
Market Signals| Indicator | ALIS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 30.02 |
| Support Level | N/A | $5.67 |
| Resistance Level | N/A | $12.91 |
| Average True Range (ATR) | 0.00 | 0.75 |
| MACD | 0.00 | -0.23 |
| Stochastic Oscillator | 0.00 | 19.75 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.